Viracta Therapeutics (NASDAQ:VIRX – Free Report) had its price target lowered by Oppenheimer from $13.00 to $11.00 in a research note released on Thursday morning, Benzinga reports. The brokerage currently has an outperform rating on the stock. Separately, HC Wainwright reaffirmed a buy rating and set a $4.00 target price on shares of Viracta Therapeutics […]